Insulin: how to pay less.
Strategies to afford insulin: copay caps, biosimilars, manufacturer programs.
Insulin is the canonical Black-health affordability crisis. Type 2 diabetes prevalence is 60 percent higher in Black adults than white adults, and rationing insulin is dangerous.
Why this matters for Black patients
The federal $35-per-month Medicare copay cap, the Inflation Reduction Act, and several state-level laws have brought relief, but the cash-pay market remains volatile. Knowing where to look matters.
Strategies to pay less
Cost Plus Drugs
Mark Cuban Cost Plus offers some insulin formulations at substantially lower cash prices than retail.
Manufacturer copay cards
Eli Lilly, Novo Nordisk, and Sanofi all offer copay programs. Eligibility depends on insurance status — some programs exclude Medicare, some don't.
State pharmaceutical assistance
Several states (NJ, NY, CT, RI, others) operate state insulin programs alongside federal benefits.
Biosimilar substitution
Biosimilar insulins (Semglee, Rezvoglar) cost substantially less than the brand-name versions they reference.